Characteristics of Patients on Non-Daily and Daily Dutasteride Compared to Cytoreduction Naive Patients
March 2013
in “
The Journal of Urology
”
TLDR Non-daily Dutasteride is more cost-effective and has lower cancer incidence than daily treatment.
This study compared the characteristics and outcomes of patients on non-daily and daily Dutasteride treatment to those who were cytoreduction naive. Out of 896 patient charts reviewed, 364 met the inclusion criteria. The non-daily group had 125 patients, the daily group had 114, and the control group had 125. The daily treatment group was older, with an average age of 74 years. The biopsy interval was longer for the non-daily group (94 months) compared to the daily group (49 months). PSA reduction was greatest in the daily group, with an average decrease of 3.4 ng/ml. Cancer incidence was lowest in the non-daily group at 4.8%, compared to 11.4% in the daily group and 16.8% in the control group. The cost of daily treatment was significantly higher at $1560 per year compared to $206 per year for once-a-week treatment. Non-daily treatment was more cost-effective, and although higher grade tumors were observed in the daily and no treatment groups, this was not statistically significant.